These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34995404)

  • 1. Lifestyle changes during the coronavirus disease 2019 pandemic impact metabolic dysfunction-associated fatty liver disease.
    Fujii H; Nakamura N; Fukumoto S; Kimura T; Nakano A; Nadatani Y; Tauchi Y; Nishii Y; Takashima S; Kamada Y; Watanabe T; Kawada N
    Liver Int; 2022 May; 42(5):995-1004. PubMed ID: 34995404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between Healthy Lifestyle and All-Cause Mortality in Individuals with Metabolic Associated Fatty Liver Disease.
    Wang X; Wang A; Zhang R; Cheng S; Pang Y
    Nutrients; 2022 Oct; 14(20):. PubMed ID: 36296904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthy Lifestyle and the Risk of Metabolic Dysfunction-Associated Fatty Liver Disease: A Large Prospective Cohort Study.
    Chang Q; Zhang Y; Zhang T; Liu Z; Cao L; Zhang Q; Liu L; Sun S; Wang X; Zhou M; Jia Q; Song K; Ding Y; Zhao Y; Niu K; Xia Y
    Diabetes Metab J; 2024 Mar; ():. PubMed ID: 38503277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease.
    Jeeyavudeen MS; Chaudhari R; Pappachan JM; Fouda S
    World J Gastroenterol; 2023 Jan; 29(3):487-502. PubMed ID: 36688018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of Combined Lifestyle Factors with MAFLD and the Specific Subtypes in Middle-Aged and Elderly Adults: The Dongfeng-Tongji Cohort Study.
    Li H; Cao Z; Li J; King L; Zhang Z; Zhao Y; Zhang S; Song Y; Zhang Q; Chen L; Tang Y; Dai L; Yao P
    Nutrients; 2023 Oct; 15(21):. PubMed ID: 37960242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of alcohol on newly developed metabolic dysfunction-associated fatty liver disease in both sexes: A longitudinal study.
    Sogabe M; Okahisa T; Kagawa M; Ueda H; Kagemoto K; Tanaka H; Kida Y; Tomonari T; Taniguchi T; Okamoto K; Miyamoto H; Sato Y; Nakasono M; Takayama T
    Clin Nutr; 2023 May; 42(5):810-816. PubMed ID: 37043935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
    Moon JH; Kim W; Koo BK; Cho NH;
    Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Non-Alcoholic Fatty Liver Disease and Metabolic-Associated Fatty Liver Disease with COVID-19-Related Intensive Care Unit Outcomes: A Systematic Review and Meta-Analysis.
    Jagirdhar GSK; Pattnaik H; Banga A; Qasba RK; Rama K; Reddy ST; Bucharles ACF; Kashyap R; Elmati PR; Bansal V; Bains Y; DaCosta T; Surani S
    Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512051
    [No Abstract]   [Full Text] [Related]  

  • 9. Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study.
    Fukunaga S; Nakano D; Kawaguchi T; Eslam M; Ouchi A; Nagata T; Kuroki H; Kawata H; Abe H; Nouno R; Kawaguchi K; George J; Mitsuyama K; Torimura T
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34067258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 Pandemic: Insights into Interactions between SARS-CoV-2 Infection and MAFLD.
    Chen H; Chen Q
    Int J Biol Sci; 2022; 18(12):4756-4767. PubMed ID: 35874945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatty liver with metabolic disorder, such as metabolic dysfunction-associated fatty liver disease, indicates high risk for developing diabetes mellitus.
    Miyake T; Matsuura B; Furukawa S; Ishihara T; Yoshida O; Miyazaki M; Watanebe K; Shiomi A; Nakaguchi H; Yamamoto Y; Koizumi Y; Tokumoto Y; Hirooka M; Takeshita E; Kumagi T; Abe M; Ikeda Y; Iwata T; Hiasa Y
    J Diabetes Investig; 2022 Jul; 13(7):1245-1252. PubMed ID: 35167194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bidirectional Relationship Between Hyperuricemia and Metabolic Dysfunction-Associated Fatty Liver Disease.
    Yang C; He Q; Chen Z; Qin JJ; Lei F; Liu YM; Liu W; Chen MM; Sun T; Zhu Q; Wu Y; Zhuo M; Cai J; Mao W; Li H
    Front Endocrinol (Lausanne); 2022; 13():821689. PubMed ID: 35250880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic Associated Fatty Liver Disease (MAFLD) and COVID-19 Infection: An Independent Predictor of Poor Disease Outcome?
    Milivojević V; Bogdanović J; Babić I; Todorović N; Ranković I
    Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629728
    [No Abstract]   [Full Text] [Related]  

  • 14. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight.
    Vasques-Monteiro IML; Souza-Mello V
    World J Gastroenterol; 2021 Apr; 27(16):1738-1750. PubMed ID: 33967554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of alcohol consumption on metabolic dysfunction-associated fatty liver disease development and remission: A longitudinal cohort study.
    Sogabe M; Okahisa T; Kagawa M; Kashihara T; Fujmoto S; Kawaguchi T; Yokoyama R; Kagemoto K; Tanaka H; Kida Y; Tomonari T; Kawano Y; Sato Y; Nakasono M; Takayama T
    Eur J Clin Invest; 2024 Apr; ():e14221. PubMed ID: 38634705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC.
    Conci S; Cipriani F; Donadon M; Marchitelli I; Ardito F; Famularo S; Perri P; Iaria M; Ansaloni L; Zanello M; La Barba G; Patauner S; Pinotti E; Molfino S; Germani P; Romano M; Sciannamea I; Ferrari C; Manzoni A; Troci A; Fumagalli L; Delvecchio A; Floridi A; Memeo R; Chiarelli M; Crespi M; Zimmitti G; Griseri G; Antonucci A; Zanus G; Tarchi P; Baiocchi GL; Zago M; Frena A; Ercolani G; Jovine E; Maestri M; Valle RD; Grazi GL; Romano F; Giuliante F; Torzilli G; Aldrighetti L; Ruzzenente A;
    Eur J Surg Oncol; 2022 Jan; 48(1):103-112. PubMed ID: 34325939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic performance of an index based on lactic dehydrogenase and transaminases for patients with liver steatosis and COVID-19.
    Macías-Rodríguez RU; Solís-Ortega AA; Ornelas-Arroyo VJ; Ruiz-Margáin A; González-Huezo MS; Urdiales-Morán NA; Román-Calleja BM; Mayorquín-Aguilar JM; González-Regueiro JA; Campos-Murguía A; Toledo-Coronado IV; Chapa-Ibargüengoitia M; Valencia-Peña B; Martínez-Cabrera CF; Flores-García NC
    World J Gastroenterol; 2022 Oct; 28(37):5444-5456. PubMed ID: 36312835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of metabolic-associated fatty liver disease (MAFLD) in adults: a population-based study in Northeastern Iran.
    Taheri E; Moslem A; Mousavi-Jarrahi A; Hatami B; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR
    Gastroenterol Hepatol Bed Bench; 2021; 14(Suppl1):S102-S111. PubMed ID: 35154609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD.
    Nguyen VH; Le MH; Cheung RC; Nguyen MH
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2172-2181.e6. PubMed ID: 34033923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.